UK: Proposal To Make Clinical Trials Less Risky And Online Drug Sales Safer

Last Updated: 22 January 2013
Article by Alison Dennis, Mark Hodgson, Beverley Potts and Beatriz San Martín

Executive summary

UK Government and EU Commission asking the pharma industry to comment on their proposals to make clinical trials for innovative drugs less risky and the purchase of online pharmaceuticals safer.

Currently, limited research can be conducted using patented products required for the regulatory approval of generic drug products without infringing UK patent rights. Clinical trials for new drugs are not exempt, which leaves a risk of being sued and increases the financial burden on companies conducting trials in the UK.  The UK government is therefore inviting comments on its proposal to exempt from patent infringement activities required to secure regulatory approval to market all drugs and/ or necessary to support health technology assessment. This article looks in more detail at the proposal and our concerns regarding its implementation. The consultation closes on 19 December 2012

The EU Commission has also been consulting on implementing a logo for legally operating online pharmacies. The aim is to make it safer to buy pharmaceutical products online by allowing consumers to verify an authorised seller by clicking on the logo. The article reviews the current consultation, which seeks opinions on the logo and the technical and cryptographic requirements for verification of the logo's authenticity. The deadline for comments is 17 January 2013

The UK Government and EU Commission are currently asking the pharmaceutical industry to comment on their proposals to make clinical trials for innovative drugs less risky and the online sale of pharmaceuticals safer for consumers.

1. Making the UK a more favourable place to trial new drugs

The UK Government has launched a consultation setting out its proposal for making the UK a more favourable place for pharmaceutical companies to carry out research and development regarding innovative drugs. "The [Intellectual Property Office ("IPO") is proposing to make changes to the Patents Act 1977 to make the system fairer by allowing clinical and field trials for new drugs to be carried out without risking being sued for patent infringement".


Under current UK patent law, patented products may be used in research and tests required for the regulatory approval of generic drug products, without infringing the rights of the patent owners. However, clinical trials for new drugs are not exempt from patent infringement. Nevertheless, there are many instances when a company may need to use a patented drug in a clinical trial. For example, a company may need to compare its new drug to a patented product or may need to develop therapies, which combine the use of its new drug and a patented product. The IPO claims that the proposal removes the current risk of being sued, reduces the financial burden placed on companies conducting trials and creates a more supportive environment for research and development in the UK.

Patent laws in most European countries include an experimental use exemption to infringement (the "Research Exception") in line with international agreements. In the UK, the Research Exception is set out in section 60(5)(b) of the Patents Act 1977 but this has been defined narrowly by the UK Courts. Trials carried out to find out whether something works can be regarded as an experiment and this should include Phase I and Phase II trials. However, trials carried out to collect further data e.g. to demonstrate to a third party that a product works as in Phase III trials may not be included. Section 60(5)(i) of the Patents Act 1977 also exempts certain activities performed to obtain regulatory approval for generic drugs (the so-called "Bolar Exception"). However, this exemption does not extend to innovative drugs, unlike in other EU countries such as Germany.


The proposal is therefore to amend section 60(5) of the Patents Act 1977 to provide an exception to patent infringement for activities necessary:

(i)  to secure regulatory approval to market all drugs (i.e. acts required by the Medicines and Healthcare products Regulatory Agency ("MHRA") or European Medicines Agency ("EMA")); and/ or

(ii) to support health technology assessment such as those conducted by National Institute for Health and Clinical Excellence ("NICE").

General comments on the proposal have been invited, although there are also a number of more specific questions:

  • Whether the amendment should exempt activities required to secure regulatory approval to market innovative drugs in: (i) all countries; or (ii) in the EU and EEA only. In addition, whether it should exempt activities necessary for health technology assessment; 
  • The costs that would be saved or the losses that would be suffered if the exception were in place;
  • Why stakeholders might risk infringing patents in preparing or running a trial involving innovative drugs;
  • Comments on the definitions of: (i) "Generic Drugs" ("Medicinal products to which the derogations in paragraphs 1 to 5 of article 13 of Directive 2011/82/EC or paragraphs 1 to 4 of Article 10 of Directive 2001/83/EC applies when seeking marketing authorisation"); and (ii) "Innovative Drugs" (those to which those exemptions do not apply); and
  • Comments on whether the exemptions should apply to micro-businesses.


Whilst we welcome the consultation, we have several concerns about the form in which the exemption may be implemented. Thus, the potential inclusion of 'activities necessary for health technology assessment' in the exemption is too nebulous as it has the potential to include marketing activities which arguably should not be exempted.  If health technology assessments are included within the scope of the exemption the activities should be clearly defined and of limited scope.  Further, if the aim of the exercise is to place the UK on an equal footing with other European states, such as Germany, so as to promote clinical trials to take place in the UK, then the exemption should cover clinical trials in any country, not just EU or EAA Member States.  This would also prevent unnecessary litigation in cases where clinical trials are conducted with a view to obtaining regulatory approval in both EU/EEA countries and other countries.

Nonetheless, the proposed changes should provide some welcome legal certainty in this area, particularly in relation to Phase III trials. The pharmaceutical industry has been keen to change the way that clinical trials are treated with a previous consultation showing that 94% of participants wanted some form of change. The IPO now states that this consultation "offers a formal opportunity to shape the patent infringement provisions so that they can better support growth in this key industry sector". Subject to the outcome of the consultation, the government is hoping to implement any changes by 1 October 2013.

Deadline: Responses to the Consultation need to be submitted by 19 December 2012.

See full Consultation document here.

2. Proposed EU Logo for authorised Online Pharmacies

Meanwhile, the European Commission has released a Consultation on "Implementing a Common Logo for Legally-Operating Online Pharmacies/ Retailers offering Medicinal Products for Human Use for Sale at a Distance to the Public ("Online Pharmacies")". The aim is to make online shopping of pharmaceutical products safer by allowing consumers to click on a common logo to verify whether the Online Pharmacy is authorised.

In July 2011, Directive 2001/62/EC (the "Online Pharmacy Directive") was published, which introduced EU-wide rules for Online Pharmacies. These included the concept that any legally operating Online Pharmacy should display a common logo on every page of any website offering medicinal products (the "Common Logo"). The idea is that the Common Logo should be recognisable throughout the EU and should enable consumers to identify the Member State where the Online Pharmacy is established.

Member States are also obliged to set up a dedicated website providing a national list of legally operating Online Pharmacies (the "National List") and a hyperlink to the website of the respective operators. The Common Logo should contain a reciprocal hyperlink to the entry on the National List (the "Reciprocal Link"), which should allow customers to verify the authenticity of the logo displayed on the webpage of the Online Pharmacy.

The current Consultation seeks opinions on the design of the Common Logo and the technical and cryptographic requirements for verification of its authenticity.

Design of the Common Logo

The Commission asks for comments on two suggestions for the Common Logo:

Option 1:

Option 2:

The Common Logo will also have to include a national element and text making it clear that the presence of the Common Logo in itself is not sufficient to guarantee authenticity (because the logo may have been copied). The suggested text is "Click to check the website". The Consultation requests any comments on the national element, the text associated with the Common Logo and the size and position of the logo.

Technical, electronic and cryptographic requirements for verification of the authenticity of the common logo

In order for the Reciprocal Link to work reliably, the EU Commission suggests that it might be necessary to encrypt the information transit between the Common Logo and the National List. The Commission also suggests that the EU Medicines Agency and Member States should educate the public that the presence of the Common Logo doesn't itself guarantee authenticity: consumers have to verify the National List by clicking on the Common Logo. The Consultation asks for any comments on these ideas.

The deadline for commenting on this Consultation is 17 January 2013. The European Commission will then adopt implementing acts and Member States will have until 2014 to implement the Directive's provisions.


Fake medicines that have not been checked for safety and efficacy are a major threat to public health. EU Customs and other public authorities are seizing more of these dangerous medicines each year. An online logo, which will help consumers to buy safe medicines online and prevent falsified medicines entering the legal supply chain must therefore be welcomed. As websites selling counterfeit goods are generally becoming more sophisticated, authorised businesses need to keep ahead of the game in helping consumers to differentiate between authentic and unauthorised goods. The technical requirements of these authentication procedures should be considered carefully and this consultation is a good opportunity to ensure that the proposed system works correctly.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Beatriz San Martín
In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions